on November 1, 2004
Published online before print October 25, 2004, doi: 10.1161/01.CIR.0000147275.50550.68
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on December 1, 2003
From the Heart Institute (InCor), University of Sao Paulo Medical School, Sao Paulo, Brazil (P.A.L.); Erasmus Medical Center, Rotterdam, the Netherlands (P.T.v.D., P.W.S.); William Beaumont Hospital, Royal Oak, Mich (N.M., W.W.O.); and Brigham and Women’s Hospital, Boston, Mass (R.E.K.). * To whom correspondence should be addressed. E-mail: p.w.j.c.serruys{at}erasmusmc.nl.
Background--We investigated the pattern of late luminal loss after sirolimus-eluting or bare stent implantation. Methods and Results--The study population comprised 238 patients treated with sirolimus-eluting stents and 526 patients treated with conventional stents. The distribution of late loss of sirolimus stents was largely skewed to the right and differed from the distribution for bare stents. When divided according to the presence of binary restenosis (diameter stenosis >50%), restenotic lesions in the bare stent group (26.0%) had a late loss of 1.40±0.64 mm and in the sirolimus group (7.9%) of 1.16±0.76 mm. Nonrestenotic lesions in the bare stent group had a late loss of 0.58±0.44 mm, whereas the late loss of nonrestenotic lesions in the sirolimus group remained close to zero (-0.05±0.33 mm). Differences between poststenting and follow-up measurements in the sirolimus group (late loss) resembled variations observed in repeated angiographic measurements, as assessed from a random sample of 30 segments measured repeatedly. After multivariate adjustment, stent type did not influence the degree of late loss in restenotic lesions. However, nonrestenotic bare stents had a significantly larger estimated luminal loss (0.58 mm; 95% CI, 0.52 to 0.65) than sirolimus-eluting stents, for which the predicted late loss was almost 0 (-0.04 mm; 95% CI, -0.10 to 0.02). Conclusions--The pattern of late loss after sirolimus-eluting stent implantation follows a peculiar behavior, different from lesions treated with conventional stents. Whether this is explained by an unusual statistical distribution or a biological all-or-none response of restenosis after sirolimus-eluting stenting remains to be investigated.
Revised on June 30, 2004
Accepted on July 14, 2004
Comparison of Late Luminal Loss Response Pattern After Sirolimus-Eluting Stent Implantation or Conventional Stenting
Pedro A. Lemos MD, PhD,
Key words: restenosis • statistics • stents
This article has been cited by other articles:
 |
|
 |
|
  C. Herdeg, K. Gohring-Frischholz, K. K. Haase, T. Geisler, C. Zurn, U. Hartmann, J. Wohrle, T. Nusser, J. Dippon, A. E. May, et al. Catheter-Based Delivery of Fluid Paclitaxel for Prevention of Restenosis in Native Coronary Artery Lesions After Stent Implantation Circ Cardiovasc Interv, August 1, 2009; 2(4): 294 - 301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Pocock, A. J. Lansky, R. Mehran, J. J. Popma, M. P. Fahy, Y. Na, G. Dangas, J. W. Moses, T. Pucelikova, D. E. Kandzari, et al. Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials. J. Am. Coll. Cardiol., January 1, 2008; 51(1): 23 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Cosgrave, G. Melzi, S. Corbett, G. G.L. Biondi-Zoccai, P. Agostoni, R. Babic, F. Airoldi, A. Chieffo, G. M. Sangiorgi, M. Montorfano, et al. Comparable Clinical Outcomes With Paclitaxel- and Sirolimus-Eluting Stents in Unrestricted Contemporary Practice J. Am. Coll. Cardiol., June 19, 2007; 49(24): 2320 - 2328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Camenzind, P. G. Steg, and W. Wijns A Cause for Concern Circulation, March 20, 2007; 115(11): 1440 - 1455. [Full Text] [PDF]
|
|
|
|
 |
|
 J. C.J. Sun, J. W. Eikelboom, P. Agostoni, G. M. Sangiorgi, G. G. Biondi-Zoccai, B. Scheller, M. Bohm, and E. Camenzind Treatment of Restenosis with a Paclitaxel-Coated Balloon Catheter N. Engl. J. Med., March 8, 2007; 356(10): 1071 - 1073. [Full Text] [PDF]
|
|
|
|
|
|
J. Fajadet, W. Wijns, G.-J. Laarman, K.-H. Kuck, J. Ormiston, T. Munzel, J. J. Popma, P. J. Fitzgerald, R. Bonan, R. E. Kuntz, et al. Randomized, Double-Blind, Multicenter Study of the Endeavor Zotarolimus-Eluting Phosphorylcholine-Encapsulated Stent for Treatment of Native Coronary Artery Lesions: Clinical and Angiographic Results of the ENDEAVOR II Trial Circulation, August 22, 2006; 114(8): 798 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Seabra-Gomes Percutaneous coronary interventions with drug eluting stents for diabetic patients. Heart, March 1, 2006; 92(3): 410 - 419. [Full Text] [PDF]
|
|
|
|
|
|
S. G. Ellis, J. J. Popma, G. W. Stone, and M. E. Russell Restenosis, Statistics, and Reasonable Inferences J. Am. Coll. Cardiol., January 17, 2006; 47(2): 470 - 471. [Full Text] [PDF]
|
|
|
|
|
|
M. Sabate, P. Jimenez-Quevedo, D. J. Angiolillo, J. A. Gomez-Hospital, F. Alfonso, R. Hernandez-Antolin, J. Goicolea, C. Banuelos, J. Escaned, R. Moreno, et al. Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary Revascularization in Diabetic Patients: The Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial Circulation, October 4, 2005; 112(14): 2175 - 2183. [Abstract] [Full Text] [PDF]
|
|